ArticleThe world journal of men's health2026
Clinical Effects and Safety Outcomes of Platelet-Rich Plasma Therapy in Patients with Vasculogenic Erectile Dysfunction: A Systematic Review and Meta-Analysis.
Article in The world journal of men's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intracavernosal Botulinum Toxin Injection for Erectile Dysfunction: A Comprehensive Systematic Review.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeErectile dysfunction (ED) significantly impacts quality of life and intimate relationships. ED results from a complex interaction of physiological, psychological, and lifestyle factors. While conventional treatments focus on symptom management, regenerative therapies like platelet-rich plasma (PRP) aim to address underlying causes, offering curative potential. However, evidence for PRP's efficacy in vasculogenic ED remains inconclusive. This systematic review and meta-analysis (SRMA) evaluates the effectiveness of penile PRP injections for vasculogenic ED and updates clinical guidelines based on recent evidence. MATERIALS AND
methodsConducted per MOOSE guidelines and registered with PROSPERO (CRD42023430295), this SRMA included observational studies and randomized controlled trials (RCTs) assessing PRP for vasculogenic ED. The PECOS framework guided eligibility, focusing on RCTs comparing PRP to placebo for meta-analysis. Data on study characteristics, PRP protocols, and outcomes using validated erectile function measures and penile Doppler parameters were extracted. Quality was assessed using Cochrane risk of bias and CONSORT guidelines. Statistical analysis employed random or fixed-effects models based on heterogeneity, with publication bias evaluated
resultsOf 111 abstracts screened, 28 met inclusion criteria, and 3 RCTs alongside 2 observational comparative studies were reviewed. Meta-analysis of the RCTs showed significant improvement in erectile function for PRP versus placebo (mean difference 3.28, 95% confidence interval 1.46-5.11, p<0.001). Sensitivity analysis confirmed result's robustness, and no publication bias was detected. Side effects were rare, with isolated cases of plaque formation and hematoma. Studies combining PRP with low-intensity shock wave therapy showed enhanced efficacy.
conclusionsPRP therapy appears promising for vasculogenic ED, but additional research is necessary to establish definitive clinical guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.